Research programme: small molecule therapeutics - Nimbus Therapeutics

Drug Profile

Research programme: small molecule therapeutics - Nimbus Therapeutics

Alternative Names: NDI-031232; NDI-031301; NDI-031302; NDI-031407

Latest Information Update: 04 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nimbus Therapeutics
  • Class Small molecules
  • Mechanism of Action Interferon inhibitors; Interferon receptor agonists; KRAS protein inhibitors; TYK2 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Ankylosing spondylitis; Cancer; Inflammation

Most Recent Events

  • 03 Nov 2017 Preclinical trials in Ankylosing spondylitis in USA (PO)
  • 03 Nov 2017 Pharmacodynamics data from a preclinical trial in Ankylosing spondylitis presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting (ACR/ARHP-2017)
  • 03 Dec 2016 Pharmacodynamic results from a preclinical study in Cancer reported at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-Hem-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top